Erasca is a developer of oncology drugs intended provide precision oncology options.
Erasca's drugs are being developed through multiple discovery.
Erasca was founded in 2018 by Jonathan E. Lim. The company is headquartered in San Diego, California.
Erasca has assembled a robust pipeline of targeted therapies directed at undisclosed targets through in-house drug discovery, as well as active pipeline expansion through collaborations with world-class academic and biopharmaceutical organizations.
Erasca is backed by ARCH Venture Partners, Cormorant Asset Management, EDBI, Invus, City Hill Ventures, Colt Ventures and others. The company raised $200M in a Series B round on Apr 27, 2020. This brings Erasca's total funding to $264M to date.